These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31531516)

  • 1. Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?
    Ascef BO; Silva RGLD; Oliveira Júnior HA; Soárez PC
    Cad Saude Publica; 2019 Sep; 35(9):e00087219. PubMed ID: 31531516
    [No Abstract]   [Full Text] [Related]  

  • 2. Health technology assessment of biosimilars worldwide: a scoping review.
    Ascef BO; Lopes ACF; de Soárez PC
    Health Res Policy Syst; 2020 Aug; 18(1):95. PubMed ID: 32843051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on Health Technology Assessment (HTA): Good Practices & Principles. FIFARMA's Position on HTA Processes in Latin America: The Devil Is in the Details.
    Levy A
    Value Health Reg Issues; 2017 Dec; 14():53-56. PubMed ID: 29254542
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars might not measure up to health plan expectations.
    Reinke T
    Manag Care; 2012 Oct; 21(10):12-3. PubMed ID: 23156071
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the health technology assessment of biosimilar pharmaceuticals.
    Stewart A; Aubrey P; Belsey J
    Curr Med Res Opin; 2010 Sep; 26(9):2119-26. PubMed ID: 20649394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Danish Health Technology Assessment model. A systematic review of Danish HTAs published by CEMTV from 1998 to 2004].
    Draborg EU
    Ugeskr Laeger; 2006 May; 168(21):2074-8. PubMed ID: 16768927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POTENTIAL FOR PATIENTS AND PATIENT-DRIVEN ORGANIZATIONS TO IMPROVE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT.
    Low E
    Int J Technol Assess Health Care; 2015 Jan; 31(4):226-7. PubMed ID: 26585562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment in Brazil: what do healthcare system players think about it?
    Ferraz MB; Soárez PC; Zucchi P
    Sao Paulo Med J; 2011; 129(4):198-205. PubMed ID: 21971894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAKEHOLDERS' PERCEPTIONS OF HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
    Ozturk K; Karadayı B; Şener O
    Int J Technol Assess Health Care; 2018 Jan; 34(1):97-104. PubMed ID: 29151380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact assessment of Iran's health technology assessment programme.
    Yazdizadeh B; Mohtasham F; Velayati A
    Health Res Policy Syst; 2018 Feb; 16(1):15. PubMed ID: 29471838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HEALTH TECHNOLOGY ASSESSMENT FOR DECISION MAKING IN LATIN AMERICA: GOOD PRACTICE PRINCIPLES.
    Pichon-Riviere A; Soto NC; Augustovski FA; García Martí S; Sampietro-Colom L
    Int J Technol Assess Health Care; 2018 Jan; 34(3):241-247. PubMed ID: 29888696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of health technology assessment in China: New challenges.
    Chen Y; He Y; Chi X; Wei Y; Shi L
    Biosci Trends; 2018; 12(2):102-108. PubMed ID: 29760354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar medicines - Review.
    Dos Reis C; Teixo R; Mendes F; Cruz RS
    Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.